MUSC Hollings Cancer Center - Report to the Community 2026 - Flipbook - Page 9
Antibody halts
triple-negative
breast cancer in
preclinical models
H
ollings Cancer Center researchers have
developed an antibody that attacks triplenegative breast cancer on multiple fronts:
slowing tumor growth and spread, strengthening the
immune response and killing cancer cells that have
become resistant to chemotherapy.
Triple-negative breast cancer is one of the most
aggressive and treatment-resistant forms of breast
cancer. Unlike other cancers, it lacks receptors that can
be targeted by many therapies, leaving patients with
fewer treatment options.
The new antibody targets SFRP2, a protein that helps
cancer grow. The work builds on nearly two decades
of research by Hollings breast surgical oncologist
Nancy Klauber-DeMore, M.D.
In preclinical models, the antibody effectively “retrained”
immune cells called macrophages from a cancersupporting state to a cancer-昀椀ghting state. It also
reinvigorated T cells, which can become exhausted and
lose their ability to attack cancer.
Mice treated with the antibody developed far fewer lung
metastases, and the treatment concentrated in tumors
rather than healthy tissues. Importantly, it also killed
triple-negative breast cancer cells that had become
resistant to a common chemotherapy drug.
“Those are very encouraging 昀椀ndings …
because they suggest the therapy may be
effective even when standard treatments fail,”
said Klauber-DeMore.
The antibody has been licensed to Charleston-based
Innova Therapeutics, which is working to raise funding for
a 昀椀rst-in-human clinical trial.
Nature Communications
JAMA Oncology
Dual targeting of tumoral cells and immune microenvironment by
blocking the IL-33/IL1RL1 pathway
State-level public awareness of HPV, HPV vaccine, and association with cancer
Deshmukh A, Graboyes E, Sonawane K
Paczesny S, Wrangle J
Report to the Community 2026 | 7